The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells

Trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody–drug conjugate with a topoisomerase I inhibitor deruxtecan (DXd), exhibits an excellent anti-tumor effect in previously treated HER2-positive tumors. A recent study demonstrated that T-DXd not only suppressed tumor growth but also enhanced an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Shotaro, Mimura, Kosaku, Matsumoto, Takuro, Thar Min, Aung Kyi, Ito, Misato, Nakano, Hiroshi, Neupane, Prajwal, Kanke, Yasuyuki, Okayama, Hirokazu, Saito, Motonobu, Momma, Tomoyuki, Watanabe, Yohei, Hanayama, Hiroyuki, Hayase, Suguru, Saze, Zenichiro, Kono, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376901/
https://www.ncbi.nlm.nih.gov/pubmed/34413454
http://dx.doi.org/10.1038/s41598-021-96521-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376901/
https://www.ncbi.nlm.nih.gov/pubmed/34413454
http://dx.doi.org/10.1038/s41598-021-96521-2

Ejemplares similares